• Novel Therapies: Using GLP-1 Receptor Agonists in Cardiorenal Metabolic Syndrome

  • Aug 20 2024
  • Length: 26 mins
  • Podcast

Novel Therapies: Using GLP-1 Receptor Agonists in Cardiorenal Metabolic Syndrome

  • Summary

  • Join Drs Nihar Desai and Matthew Cavender as they discuss the history, studies, and implementation of GLP-1 receptor agonists for people with cardiorenal metabolic syndrome.

    Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999842. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

    Resources

    Glucagon-Like Peptide-1 Receptor Agonists https://www.ncbi.nlm.nih.gov/books/NBK551568/#:~:text=Glucagon%2Dlike%20peptide%2D1%20(,options%20for%20these%20endocrine%20diseases.

    Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death From Cardiovascular Causes https://pubmed.ncbi.nlm.nih.gov/17517853/

    Guidance for Industry on Diabetes Mellitus-Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes; Availability https://www.federalregister.gov/documents/2008/12/19/E8-30086/guidance-for-industry-on-diabetes-mellitus-evaluating-cardiovascular-risk-in-new-antidiabetic

    Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes https://pubmed.ncbi.nlm.nih.gov/27295427/

    Effects of Oral Semaglutide on Cardiovascular Outcomes in Individuals With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease: Design and Baseline Characteristics of SOUL, a Randomized Trial https://pubmed.ncbi.nlm.nih.gov/36945734/

    Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes https://pubmed.ncbi.nlm.nih.gov/37952131/

    Heart Failure With Preserved Ejection Fraction (HFpEF) https://www.ncbi.nlm.nih.gov/books/NBK599960/

    Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial https://pubmed.ncbi.nlm.nih.gov/27483064/

    Semaglutide Versus Placebo in People With Obesity-Related Heart Failure With Preserved Ejection Fraction: A Pooled Analysis of the STEP-HFpEF and STEP-HFpEF DM Randomised Trials https://pubmed.ncbi.nlm.nih.gov/38599221/

    Interpreting the Kansas City Cardiomyopathy Questionnaire in Clinical Trials and Clinical Care: JACC State-of-the-Art Review https://pubmed.ncbi.nlm.nih.gov/33183512/

    Comparison of Tirzepatide and Dulaglutide on Major Adverse Cardiovascular Events in Participants With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: SURPASS-CVOT Design and Baseline Characteristics https://pubmed.ncbi.nlm.nih.gov/37758044/

    Coordinated Care to Optimize Cardiovascular Preventive Therapies in Type 2 Diabetes: A Randomized Clinical Trial https://pubmed.ncbi.nlm.nih.gov/36877177/

    Show more Show less
activate_Holiday_promo_in_buybox_DT_T2

What listeners say about Novel Therapies: Using GLP-1 Receptor Agonists in Cardiorenal Metabolic Syndrome

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.